All Stories

  1. Effect of polymorphic variants of genes of neurotrophic factors on the disease severity and the anxiety level in patients with affective disorders and comorbid alcohol dependence
  2. Glutathione antioxidant pathways in patients with schizophrenia: relationship with metabolic syndrome
  3. Polymorphic variants of proinflammatory cytokine genes in affective disorders and in cases of comorbidity with alcohol addiction
  4. Constitutional and biological predictors of the risk of suicidal behavior in mental disorders
  5. Neurocognitive deficits in schizophrenia and polymorphic variants of protein kinase signaling pathway genes: search for associations
  6. Immunobiological markers of the effectiveness of antipsychotic therapy in patients with schizophrenia
  7. Polymorphism of neurotrophin genes and aggressive behavior in patients with affective disorders
  8. Assessment of the change over time of serum matrix metalloproteinases and vascular endothelial growth factor in the acute period of ischemic stroke
  9. Protein Kinase Expression of the AKT/mTOR Signaling Pathway in Peripheral Mononuclear Cells of Schizophrenia Patients: A Pilot Study
  10. Myeloperoxidase, Cathepsin D, and Plasminogen Activation Inhibitor Type 1 as Potential Biomarkers of Schizophrenia (pilot study)
  11. Positive and Negative Symptoms of Schizophrenia and Polymorphic Variants of the TCF4 Gene: Pilot Associative Study
  12. Регуляторный потенциал полиморфных вариантов генов BDNF-опосредованных протеинкиназных сигнальных путей, ассоциированных с шизофренией
  13. Polymorphic Variants of Neurotrophic Factor Genes in Affective Disorders: Pilot Study
  14. Neuroinflammation in Schizophrenia: An Overview of Evidence and Implications for Pathophysiology
  15. Polymorphic variant of NQO1 rs1800566 and antipsychotic-induced metabolic disorders in patients with schizophrenia
  16. Academic Psychiatric School in Siberia: History of Formation and Horizons of Development. Interview with an Academician of RAS Nikolay A. Bokhan
  17. The Effect of Metabolic Syndrome and its Individual Components on the Duration of the QTc Interval in Different Gene Carriers of the Nitric Oxide Synthase 1 Adapter Protein Gene in Patients with Schizophrenia
  18. The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study
  19. Neuroinflammatory and neurodegenerative aspects of Parkinson’s disease
  20. The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy
  21. Прогнозирование эффективности фармакотерапии у больных депрессивными расстройствами на основе генетических показателей
  22. Blood Growth Factor Levels in Patients with Systemic Lupus Erythematosus: High Neuregulin-1 is Associated with Comorbid Cardiovascular Pathology
  23. Взаимосвязь тромбоцитарных факторов роста с клиническими и клинико-динамическими характеристиками у пациентов с аффективными расстройствами
  24. Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
  25. Ассоциативный анализ гаплотипов и регуляторный потенциал генов серотониновых рецепторов у больных шизофренией с тардивной дискинезией
  26. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia
  27. Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study
  28. Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia
  29. Associations of serum neuromarkers with clinical features of Parkinson’s disease
  30. Serum neurofilament light chains in assessing the course of multiple sclerosis
  31. The relationship between the rs6265 polymorphism of the BDNF gene and the level of serum neurotrophic factor in patients with Parkinson’s disease
  32. Association of inflammation and chronic fatigue syndrome in patients with Parkinson’s disease
  33. Growth factors PDGF-AA, PDGF-BB and BDNF as potential differentiating biomarkers of unipolar and bipolar depression
  34. A pilot study of associations of markers of glial and neuronal degeneration with executive functions in alcohol use disorders
  35. Serum neurofilaments light chain as a diagnostic marker of multiple sclerosis
  36. Differential Expression of Proteins Associated with Bipolar Disorder as Identified Using the PeptideShaker Software
  37. Relationship of Neurospecific Serum Proteins with Clinical Features in Depressive Episode and Recurrent Depressive Disorder
  38. Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
  39. Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
  40. Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
  41. EEG Frontal Asymmetry in Unipolar and Bipolar Depression
  42. Association of Peripheral Inflammatory Biomarkers and Growth Factors Levels with Sex, Therapy and Other Clinical Factors in Schizophrenia and Patient Stratification Based on These Data
  43. Роль полиморфизма генов дофаминовой и глутаматной систем в клинической гетерогенности шизофрении и развитии антипсихотик-индуцированных побочных эффектов
  44. The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia
  45. Serum Growth Factors in Schizophrenia Patients
  46. In vitro effect of serum IgGs with oxidoreductase activities of schizophrenic patients on apoptosis level
  47. Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
  48. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
  49. Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
  50. Coherence of the electroencephalogram and peripheral markers of nerve tissue damage in depressive disorders
  51. BDNF gene RS6265 polymorphism in patients with multiple sclerosis of Tomsk region
  52. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
  53. Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis
  54. Executive dysfunction in affective disorders: differences in bipolar affective disorder and depressive episode
  55. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
  56. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
  57. Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results
  58. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  59. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  60. Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein
  61. Serum Cytokine Levels of Systemic Lupus Erythematosus Patients in the Presence of Concomitant Cardiovascular Diseases
  62. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  63. Circuits regulating pleasure and happiness – focus on potential biomarkers for circuitry including the habenuloid complex
  64. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  65. Возможные нейрофизиологические маркеры для дифференциальной диагностики биполярных и униполярных аффективных расстройств
  66. Оценка цитотоксических эффектов IgG, выделенных из сыворотки крови больных шизофренией
  67. Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1
  68. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity
  69. Current methods for predicting therapeutic response in patients with depressive disorders
  70. Correlations between clinical features of bipolar affective disorder and serum concentrations of ANKRD12 gene product, coagulation factor XIII, and cadherin 5
  71. Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia
  72. A New Paradigm to Indicate Antidepressant Treatments
  73. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  74. Assessment of serum BDNF levels in complex rehabilitation of patients with ischemic stroke using traditional approaches to the restoration of motor functions
  75. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  76. Влияние органических солей лития на содержание белков Akt/mTOR-сигнального пути в мононуклеарах периферической крови больных биполярным аффективным расстройством
  77. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  78. Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days
  79. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  80. Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
  81. Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness
  82. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  83. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  84. Features of brain activity in alcohol dependence in the task of inhibitory control
  85. Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
  86. Cognitive impairment in patients after COVID-19
  87. Влияние когнитивных функций на уровень суицидального риска у больных шизофренией
  88. Using the quantitative EEG method in predicting the response to treatment of affective disorders
  89. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  90. Модель прогнозирования метаболического синдрома у больных параноидной шизофренией
  91. Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders
  92. Glutamate Level’s in Blood Serum of Patients with Schisophrenic Spectrum and Bipolar Affective Disorder
  93. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  94. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke
  95. Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
  96. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  97. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  98. Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects
  99. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  100. IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects
  101. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  102. Clinical and laboratory assessment of the effectiveness of early rehabilitation of patients with stroke using assistive robotic tools
  103. Relationship of cognitive disorders with clinical features of alcohol dependence
  104. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  105. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  106. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  107. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia
  108. Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
  109. Суицидальное поведение больных шизофренией с метаболическим синдромом
  110. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  111. The difference in serum proteomes in schizophrenia and bipolar disorder
  112. Association of Polymorphic Variants of Brain-Derived Neurotrophic Factor Gene (Bdnf Rs6265) and Glutamate Transporter Gene of the Second Type (Slc1a2 Rs4354668) with the Course of Multiple Sclerosis in Patients Living in Tomsk Region
  113. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  114. Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD
  115. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  116. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  117. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  118. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  119. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  120. Brain pathology in schizophrenia: association with clinical and constitutional factors
  121. NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT
  122. Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature
  123. Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
  124. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  125. The evolutionary old forebrain as site of action to develop new psychotropic drugs
  126. IgG antibodies from the sera of patients degrade myelin basic protein
  127. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  128. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  129. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  130. Parkinson's disease and polymorphisms of the glutamatergic system genes GRIN2A, SLC1A2, and GRIK4
  131. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients
  132. Blood-Derived RNA- and microRNA-Hydrolyzing IgG Antibodies in Schizophrenia Patients
  133. Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia
  134. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  135. Commentary on “A non-reward attractor theory of depression”: A proposal to include the habenula connection
  136. How brain mechanism of feeling pleasure and happiness evolved during the last 560 million years.
  137. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  138. The role of the habenula in the transition from reward to misery in substance use and mood disorders
  139. Circuits regulating pleasure and happiness: evolution and role in mental disorders
  140. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  141. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  142. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  143. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  144. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  145. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  146. Circuits Regulating Pleasure and Happiness in Bipolar Disorder
  147. Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions
  148. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  149. Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates
  150. Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
  151. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  152. Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum
  153. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  154. Circuits regulating pleasure and happiness in major depression
  155. Antioxidant and Immunotropic Properties of some Lithium Salts
  156. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  157. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  158. The association of the DRD3 gene with Parkinson’s disease
  159. Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding
  160. An association of AKT1 gene polymorphism with antidepressant treatment response
  161. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  162. Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates
  163. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  164. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  165. Serum Levels of Neurosteroids in Patients with Affective Disorders
  166. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  167. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  168. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  169. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  170. Glutamate Concentration in the Serum of Patients with Schizophrenia
  171. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  172. Effects of Neuroprotector Cortexin on the Dynamics of Neuroendocrine System Parameters in Patients with Organic Emotionally Labile (Asthenic) Disorders
  173. New insights into the mechanism of drug-induced dyskinesia
  174. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  175. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  176. Effects of dehydroepiandrosterone sulfate on induced apoptosis of lymphocytes in healthy persons
  177. Study of the indices of antioxidant defense in mental maladaptation
  178. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia
  179. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
  180. The correlation between schizophrenia duration and the serum concentration of dehydroepiandrosterone sulfate
  181. The state of the antioxidant system during therapy of patients with multiple sclerosis
  182. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  183. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  184. PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3
  185. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  186. P.3.c.044 Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients
  187. P.3.d.010 Catabolic-anabolic balance and leucocytes's apoptosis in patients with schizophrenia
  188. P.2.b.011 Antidepressant therapy and apoptosis of immnocompetent cells in patients with depressive disorders
  189. P.3.c.017 Influence of atypical neuroleptic quetiapine on the serum dehydroepiandrosterone/ cortisol ratio in schizophrenia
  190. Signs of apoptosis of immunocompetent cells in patients with depression
  191. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  192. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  193. P.2.016 Influence of atypical neuroleptic on cell apoptosis in patients with schizophrenia in the course of the therapy
  194. P.1.107 Influence of pharmacotherapy on fas-receptorsand spontaneous apoptosis of lymphocytes in patients with depressive disorders
  195. Immunity system in alcoholism